Following an agreed investment by European investment company Gimv, Pharming’s minority stake of 43.85% in BioConnection will reduce to 22.98%. As a result of this transaction, Pharming will receive one-off US$ 7.5 million (EUR 6.9 million) net cash proceeds.

Pharming Group presents its preliminary financial report for the full year ended December 31, 2021.

Pharming Group presents its preliminary (unaudited) financial report for the first nine months ended September 30, 2021.

Recovery continued into Q2 2021 as patient enrollment and product demand increases

Pharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2021.

Pharming Group announces the filing of its Annual Report on Form 20-F for the year ended 31 December 2020 with the U.S. Securities and Exchange Commission (SEC)

Pharming Group N.V. announces the publication of its Annual Report for the year ended 31 December 2020. In addition, the Company’s 2021 Annual General Meeting (AGM) will be held at 16:00CET on Wednesday, 19 May 2021. The Notice to Convene, Explanatory Notes, meeting documents and Form of Proxy can be found on the Company’s website, under Investors/Shareholders’ Meetings.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended 31 December 2020.